Recognizing the positive impact of CSTDs on pharmacy staff members’ safety, progress toward 100% adoption of these devices for drug preparation continued across facilities of all sizes even through the pandemic. The marketplace remains busy with the introduction of BD’s PhaSeal Optima and Fresenius Kabi’s purchase of Corvida. CSTDs are well-rated by their users and engender solid product loyalty.
Progress toward 100% adoption of CSTDs in the pharmacy continues apace.
As facilities of all sizes move toward ubiquitous use of CSTDs in the pharmacy, purchasing activity will be strongest in facilities with 101-200 beds.
Most facilities follow the guidance from USP regarding drug vial optimization: 86% of CSTD users do not rely on this technology to extend BUDs.
Equashield, PhaSeal, OnGuard, and ChemoClave are the leading devices in use.
CSTD vendors garner high user satisfaction ratings; as such 58% have no plans to switch vendors.